Skip to main content
SpringerLink
Log in

Revised labelling for ultrasound contrast agent

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. GE Healthcare.FDA Approves Labeling Changes for GE Healthcare's Optison(Tm) (Perflutren Protein-Type A Microspheres Injectable Suspension, USP). Media Release: 21 Aug 2012. Available from: URL: http://www.gehealthcare.com

  2. International Contrast Ultrasound Society.ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents. Media Release: 21 Aug 2012. Available from: URL: http://www.icus-society.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Revised labelling for ultrasound contrast agent. React. Wkly. 1417, 3 (2012). https://doi.org/10.2165/00128415-201214170-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214170-00006

Keywords

Search

Navigation